Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system

Antzeko izenburuak

• Real-world safety of Symdeko: insights from the food and drug administration adverse event reporting system
  nork: Su Wei, et al.
  Argitaratua: (2025-10-01)
• Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system
  nork: Sentai Wang, et al.
  Argitaratua: (2025-03-01)
• Safety assessment of gemtuzumab ozogamicin: real-world adverse event analysis based on the FDA Adverse Event Reporting System
  nork: Xuexue Liu, et al.
  Argitaratua: (2025-09-01)
• Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
  nork: Zhuomiao Lin, et al.
  Argitaratua: (2025-08-01)
• Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database
  nork: Wen-Hui Liu, et al.
  Argitaratua: (2024-11-01)